These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 19516046)

  • 1. Chronic disease projections in heterogeneous ageing populations: approximating multi-state models of joint distributions by modelling marginal distributions.
    Hoogenveen RT; van Baal PH; Boshuizen HC
    Math Med Biol; 2010 Mar; 27(1):1-19. PubMed ID: 19516046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The global impact of noncommunicable diseases: estimates and projections.
    Manton KG
    World Health Stat Q; 1988; 41(3-4):255-66. PubMed ID: 3232413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Meta-analysis of the Italian studies on short-term effects of air pollution].
    Biggeri A; Bellini P; Terracini B;
    Epidemiol Prev; 2001; 25(2 Suppl):1-71. PubMed ID: 11515188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marginal estimation for multi-stage models: waiting time distributions and competing risks analyses.
    Satten GA; Datta S
    Stat Med; 2002 Jan; 21(1):3-19. PubMed ID: 11782047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computing marginal expectations for large compartmentalized models with application to AIDS evolution in a prison system.
    Yakowitz S; Blount M; Gani J
    IMA J Math Appl Med Biol; 1996 Dec; 13(4):223-44. PubMed ID: 8968784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
    Pradelli L; Iannazzo S; Zaniolo O
    Am J Cardiovasc Drugs; 2009; 9(6):383-92. PubMed ID: 19929036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
    Whitfield MD; Gillett M; Holmes M; Ogden E
    Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing chronic disease progression using non-homogeneous exponential regression Markov models: an illustration using a selective breast cancer screening in Taiwan.
    Hsieh HJ; Chen TH; Chang SH
    Stat Med; 2002 Nov; 21(22):3369-82. PubMed ID: 12407678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. tdc.msm: an R library for the analysis of multi-state survival data.
    Meira-Machado L; Cadarso-Suárez C; de Uña-Alvarez J
    Comput Methods Programs Biomed; 2007 May; 86(2):131-40. PubMed ID: 17350136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The analysis of survival data with a non-susceptible fraction and dual censoring mechanisms.
    Gagnon DR; Glickman ME; Myers RH; Cupples LA
    Stat Med; 2003 Oct; 22(20):3249-62. PubMed ID: 14518026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mixed mover-stayer model for spatiotemporal two-state processes.
    Nathoo F; Dean CB
    Biometrics; 2007 Sep; 63(3):881-91. PubMed ID: 17825018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A discrete-state discrete-time model using indirect observation.
    Isaman DJ; Herman WH; Brown MB
    Stat Med; 2006 Mar; 25(6):1035-49. PubMed ID: 16416413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneously modelling censored survival data and repeatedly measured covariates: a Gibbs sampling approach.
    Faucett CL; Thomas DC
    Stat Med; 1996 Aug; 15(15):1663-85. PubMed ID: 8858789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a global stochastic model relating the distribution of individual cell and population physiological states.
    McKellar RC; Lu X
    Int J Food Microbiol; 2005 Apr; 100(1-3):33-40. PubMed ID: 15854690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testing treatment effects in the presence of competing risks.
    Freidlin B; Korn EL
    Stat Med; 2005 Jun; 24(11):1703-12. PubMed ID: 15706579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling disease-state transition heterogeneity through Bayesian variable selection.
    Healy BC; Engler D
    Stat Med; 2009 Apr; 28(9):1353-68. PubMed ID: 19206077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Some simple tests for spatial effects around putative sources of health risk.
    Lawson AB; Williams FL; Liu Y
    Biom J; 2007 Aug; 49(4):493-504. PubMed ID: 17638283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative risk stratification in Markov chains with limiting conditional distributions.
    Chan DC; Pollett PK; Weinstein MC
    Med Decis Making; 2009; 29(4):532-40. PubMed ID: 19336745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality modeling of early detection programs.
    Lee SJ; Zelen M
    Biometrics; 2008 Jun; 64(2):386-95. PubMed ID: 17725809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.